Concepedia

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, Michael Braun, Doris Augustin, Jochem Potenberg, Katja Krauss,

The Lancet Oncology · 2022 · 83 citations · 19 references

References

19

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text

Medicine, Oncology, Pathology +14

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Antonio Llombart‐Cussac, Javier Cortés, Laia Paré et al. · The Lancet Oncology · 2017 · 341 citations

Medicine, Oncology, Pharmacology +17

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero et al. · Journal of Clinical Oncology · 2013 · 274 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Otto Metzger, Giuseppe Viale, Shayna Stein et al. · Cancer Discovery · 2021 · 240 citations · Full text

Medicine, Cancer Biology, Oncology +15